mRNA of the OY-TES-1 gene in peripheral blood and tumors in colorectal cancer

Background. One of the testicular cancer genes is the OY-TES-1 gene, which encodes a proacrosin-binding protein. This gene is known to be expressed in tumor cells.

Aim. To determinate the detection frequency of OY-TES-1 matrix ribonucleic acid (mRNA) in the peripheral blood and tumor of patients with colorectal cancer (CRC) in comparison with the clinical features of the course of a disease in order to assess the potential monitoring significance of this indicator.

Materials and methods. A method for determining the level of OY-TES-1 mRNA based on reverse transcription polymerase chain reaction (RT-PCR). The detection frequency of mRNA OY-TES-1 gene in blood and tumor samples of 66 patients with CRC, as well as the blood of healthy volunteers, was evaluated.

Results. In the peripheral blood of healthy volunteers, no OY-TES-1 mRNA was detected. In the blood of CRC patients, OY-TES-1 mRNA was detected in 13.6 % of cases. In tumors, it was found in 60,6 % of cases. OY-TES-1 mRNA in the blood and in tumor of patients with CRC was detected statistically significantly more often at stages III and IV than at stages I and II (11,0 and 4,5 times, respectively), and also many times more often in tumors with a low degree of differentiation than with highly differentiated tumors. In patients with CRC, the OY-TES-1 mRNA in tumors with metastases in organs and lymph nodes was detected many times more often than in tumors without any metastases (by 16,4 and 17,4 times respectively).

Conclusion. The data obtained indicate the absence of mRNA OY-TES-1gene in the blood of healthy individuals, the appearance of mRNA OY-TES-1 gene in the blood of CRC patients, and the possibility of using the detection of mRNA OY-TES-1 gene in the blood as an additional informative monitoring marker for colorectal cancer.

1. Liu W-S. Mammalian Sex Chromosome Structure, Gene Content, and Function in Male Fertility. Annu Rev Anim Biosci 2019;15(7):103–24. DOI: 10.1146/annurev-animal-020518-115332

2. Golyshko P.V., Novikov D.V., Ananiev S.V. et al. Cancertesticular genes in the blood and tumors of patients with colorectal cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(1):19–24. (In Russ.). DOI: 10.17650/1726-9784-2015-14-1-19-24.

3. Gu L., Sang M., Yin D. et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer. Thorac Cancer 2018;9(4):431–8. DOI: 10.1111/1759-7714.12571

4. Kanemori Y., Ryu J.H., Sudo M. et al. Two functional forms of ACRBP/sp32 are produced by pre-mRNA alternative splicing in the mouse. Biol Reprod 2013;88:105. DOI: 10.1095/biolreprod.112.107425

5. Cen Y.H., Guo W.W., Luo B. et al. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cell Biol Int 2012;36:917–22. DOI: 10.1042/CBI20120037

6. Bin L., Xiang Y., Jing L. et al. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Current Medical Science 2020;40:719–28. DOI: 10.1007/s11596-020-2241-x

7. Lin L., Nong W., Luo B. et al. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: its association with prognosis. Immunity, Inflammation and Disease 2021;9(4):1759–70. DOI: 10.1002/iid3.534

8. Kazemi-oula G., Ghafouri-Fard S., Mobasheri M.B. et al. Upregulation of RHOXF2 and ODF4 Expression in Breast Cancer Tissues. Cell Journal 2015;17:471–7. DOI:10.22074/CELLJ.2015.8

9. Bin L., Xiang Y., Rong F. et al. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Int J Clin Exp Pathol 2013;6(12):2835–45.

10. Hilal N.R., Novikov D.V., Novikov V.V., Karaulov A.V. Cancertesticular genes in colon cancer. Terapevticheskiy arkhiv = Therapeutic Archive 2017;113–7. (In Russ.). DOI: 10.17116/terarkh2017895113-117

11. Kalugin A.V., Novikov D.V., Mamaeva M.E. et al. Cancer-testis genes mRNA presence in tumor lesion and peripheral blood of endometrial cancer patients. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2022;21(2):33–9. (In Russ.). DOI: 10.17650/1726-9784-2022-21-2-33-39

12. Maus M.K., Hanna D.L., Stephens C.L. et al. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 2015;15(4):354–62. DOI: 10.1038/tpj.2014.73

13. Birkenkamp-Demtroder K., Olesen S.H., Sorensen F.B. et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54(3):374–84. DOI: 10.1136/gut.2003.036848

14. Missiaglia E., Jacobs B., D’Ario G. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25(10):1995–2001. DOI: 10.1093/annonc/mdu275

15. Xu S.Z., Ding Z.J., Zhang S.F. et al. Propensity score matching-based analysis of short-term outcomes of Laparoscopicassisted Natural Orifice Specimen Extraction for left colorectal cancer radical resection. Zhonghua Yi Xue Za Zhi 2016;96(20):1578–81. DOI: 10.3760/cma.j.issn.0376-2491. 2016.20.007

16. Dejea C.M., Wick E.C., Hechenbleikner E.M. et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 2014;111(51):18321–6. DOI: 10.1073/pnas.1406199111

17. Almutairi M.H., Alrubie T.M., Almutairi B.O. et al. The Expression Patterns of Human Cancer-Testis Genes Are Induced through Epigenetic Drugs in Colon Cancer Cells. Pharmaceutical 2022;15(11):1319. DOI: 10.3390/ph15111319

18. Thomas J., Starmans M.H.W., Yao-Tseng C. et al. The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS One 2013;8(7):e67876. DOI: 10.1371/journal.pone.0067876